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Research Article
ATP Binding Cassette Sub-family Member 2 (ABCG2)
and Xenobiotic Exposure During Early Mouse Embryonic
Stem Cell Differentiation
Mitchell B. Rosen , Susan C. Jeffay, Harriette P. Nichols,
Maria R. Hoopes, and E. Sidney Hunter III*
Background: ATP binding cassette sub-family member 2 (ABCG2) is a well-
defined efflux transporter found in a variety of tissues. The role of ABCG2
during early embryonic development, however, is not established. Previous
work which compared data from the ToxCast screening program with that
from in-house studies suggested an association exists between exposure to
xenobiotics that regulate Abcg2 transcription and differentiation of mouse
embryonic stem cells (mESC), a relationship potentially related to redox home-
ostasis. Methods: mESC were grown for up to 9 days. Pharmacological
inhibitors were used to assess transporter function with and without xenobiotic
exposure. Proliferation and differentiation were evaluated using RedDot1 and
quantiative reverse transcriptase-polymerase chain reaction, respectively.
ABCG2 activity was assessed using a Pheophorbide a-based fluorescent
assay. Protein expression was measured by capillary-based immunoassay.
Results: ABCG2 activity increased in differentiating mESC. Treatment with
K0143, an inhibitor of ABCG2, had no effect on proliferation or differentiation.
As expected, mitoxantrone and topotecan, two chemotherapeutics, displayed
increased toxicity in the presence of K0143. Exposure to K0143 in
combination with chemicals predicted by ToxCast to regulate ABCG2
expression did not alter xenobiotic-induced toxicity. Moreover, inhibition of
ABCG2 did not shift the toxicity of either tert-Butyl hydroperoxide or paraquat,
two oxidative stressors. Conclusion: As previously reported, ABCG2 serves a
protective role in mESC. The role of ABCG2 in regulating redox status,
however, was unclear. The hypothesis that ABCG2 plays a fundamental role
during mESC differentiation or that regulation of the receptor by xenobiotics
may be associated with altered mESC differentiation could not be supported.
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Introduction
ATP binding cassette sub-family member 2 (ABCG2), also
known as breast cancer resistance protein (BCRP1), is a
member of the highly conserved ABC transporter super-
family. ABCG2 is a commonly studied multidrug resistance
efflux transporter that, along with ABCB1 (P-glycoprotein
or Mdr1) and ABCC1(Mrp1), is capable of imparting prop-
erties of chemotherapeutic drug resistance and xenobiotic
protection. ABCG2 is found in the plasma membrane as a
half-transporter with the ability to form functional
homodimers or possibly higher-order multimers in a vari-
ety of tissues such as small intestine, liver, placenta, mam-
mary gland, brain, kidney, and testis. There is substantial
functional overlap among the three ABC multidrug resist-
ance transporters as well as significant structural diversity
among those compounds known to be substrates for these
transporters (for reviews see Sarkadi et al., 2004; Adachi
et al., 2007; Hardwick et al., 2007; Sharom, 2008; Robey
et al., 2009; Mo and Zhang, 2012; Stacy et al., 2013).
In addition to its role as a xenobiotic transporter,
ABCG2 is highly expressed in certain stem cell populations
where it may play a role in maintaining cells in an uncom-
mitted state. ABCG2 activity, for example, is associated
with the side-population or “SP” phenotype which was
first characterized as a population of uncommitted hema-
topoietic stem cells with increased capacity for efflux of
Hoechst 33342 (Goodell et al., 1996). Although initially
associated with ABCB1, ABCG2 has subsequently been
shown to be a significant contributor to the SP phenotype
(Zhou et al., 2001; Scharenberg et al., 2002). SP cells have
been demonstrated in a variety of adult and developing
tissues (Kim and Morshead, 2003; Martin et al., 2004; Cer-
vello et al., 2010; Oka et al., 2010; Fatima et al., 2012; Fos-
ter et al., 2013). Hence, both ABCB1 and ABCG2 have been
evaluated as potential markers of plasticity in various
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stem cell populations (for reviews see Bunting, 2002; Ding
et al., 2010).
Although ABCG2 is expressed in stem cell populations,
the role of the transporter in these cells is not fully under-
stood. SP cells have been identified within the larger popu-
lation of mouse embryonic stem cells (mESC) as a group of
pluripotent but somewhat heterogeneous cells which dis-
play characteristics of the inner cell mass and early epiblast
(Vieyra et al., 2009). RNA-interference mediated inhibition
of ABCG2 or functional blockage of the transporter with
fumitremorgin C (FTC) has been shown in mESC to induce
cell cycle arrest and reduce expression of Nanog, a key reg-
ulator of stem cell pluripotency, thus, raising the possibility
that ABCG2 may play a role in stem cell maintenance and
colony expansion (Susanto et al., 2008). Conversely, Zhou
et al. (2001) found equivalent expression of Abcg2 in SP
and non-SP populations of mESC and Erdei et al. (2013)
reported that the expression of pluripotency markers in
human embryonic stem cells was independent of ABCG2
expression. Furthermore, Abcg2-null mice display a normal
phenotype unless faced with a xenobiotic challenge such as
pheophorbide a-induced phototoxicity (Jonker et al., 2002).
A previous evaluation by our group of 310 ToxCast
Phase 1 chemicals (www.epa.gov/chemical-research/tox-
cast-dashboard) suggested an association exists between
compounds that modify ABCG2 expression and altered dif-
ferentiation of mESC. In this study, altered redox homeo-
stasis was offered as a potential mode of action for ABCG2
and other pathways proposed to modify mESC differentia-
tion (Chandler et al., 2011). Indeed, regulation of ABCG2 is
complex and its promoter contains multiple cis-regulatory
elements including response elements for hypoxia and oxi-
dative stress (reviewed by Nakanishi and Ross, 2012).
Krishnamurthy et al. (2004) reported that ABCG2 provides
resistance to hypoxia in hematopoietic cells and Susanto
et al. (2008) suggested that ABCG2 serves to protect
embryonic stem cells from oxidative stress by eliminating
protoporphyrin IX under conditions of rapid colony expan-
sion. These findings support a role for ABCG2 in maintain-
ing redox homeostasis in embryonic stem cells during
conditions of clonal expansion or xenobiotic stress.
This study tested the hypothesis that a causal link exists
between altered ABCG2 activity and chemical-induced
effects on early mESC differentiaion. Xenobiotic challenge,
including exposure to certain ToxCast Phase I compounds
and oxidative stress, was used either with or without phar-
macological inhibition of ABCG2. mESC were evaluated for
changes in cell proliferation and marker gene expression.
Materials and Methods
CHEMICALS
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless otherwise indicated. With the exception
of paraquat, all stock solutions were prepared in 100%
dimethyl sulfoxide and stored as aliquots at -808C. Para-
quat was prepared as a stock solution in sterile phosphate
buffered saline (PBS) and stored as aliquots at -808C. Tox-
Cast chemicals chosen for evaluation included Propicona-
zole (CAS 60207-90-1), Flusilazole (CAS 85509-19-9),
Pyridaben (CAS 96489-71-3), Rotenone (CAS 83-79-4),
and Imazapyr (CAS 81334-34-1).
CELLS
Pluripotent J1 mESC were purchased from ATCC (D3: CRL-
1934TM, J1: SCRC-1010TM, Manassas, VA) and maintained
following protocols adapted from ATCC. Culture methods
were described previously (Barrier et al., 2011). In brief,
pluripotent mESC were grown in gelatin-coated T25
vented tissue culture flasks (Corning #30639, Corning Life
Sciences, Tewsbury, MA) at 378C in a humidified incubator
containing 5% CO2. Maintenance media contained Knock-
out Dulbecco’s modified eagle’s medium (ThermoFisher/
Gibco, Grand Island, NY), 15% fetal bovine serum (FBS,
ThermoFisher/Gibco), 2 mM GlutaMAX (ThermoFisher/
Gibco), 0.1 mM nonessential amino acids (ThermoFisher/
Gibco), 50 U/ml Pen/Strep (ThermoFisher/Gibco), and 10
lg/ml Leukemia Inhibiting Factor (EMD Millipore, Biller-
ica, MA). Maintenance cultures of undifferentiated mESC
included a feeder layer of mitomycin-c-inactivated mouse
embryo fibroblasts (PMEF-CF, EMD Millipore). Cells were
passaged every 2 to 3 days at 70 to 80% confluence fol-
lowing digestion with TrypLE Express (ThermoFisher/
Gibco) using an initial density of 1 3 106 cells/flask. Cell
density was determined using a NucleoCounterTM Auto-
matic Cell Counter (New Brunswick Scientific, Edison, NJ).
Mouse embryonic fibroblasts were maintained in Dulbec-
co’s modified eagle’s medium containing 10% FBS, 2 mM
GlutaMAX, and 50 U/ml Pen/Strep.
PLATING AND TREATMENT OF MESC
Before treatment, mouse embryonic fibroblasts were
removed using MACSVR Technology as directed by the man-
ufacturer (Miltenyi Biotec, San Diego, CA). Enriched pluri-
potent mESC were then seeded onto 0.1% gelatin-coated
96-well plates in 100 ll media without Leukemia Inhibi-
ting Factor at a density of 2500 cells/well and allowed to
attach for 24 hr. A total of 150 ll control or treatment
media was then added to each well of the culture plate on
the morning of culture day 1. The dimethyl sulfoxide con-
centration was maintained at 0.1% in all control and treat-
ment wells. Cells were grown at 378C in a humidified
incubator containing 5% CO2 and cultures were termi-
nated on day 4, a useful early culture time point with
clearly defined changes in gene expression that were gen-
erally analogous to gastrulation in the whole embryo. In
those experiments designed to evaluate the role of ABCG2
in mESC following exposure to ToxCast chemicals, control
and treatment media were refreshed on a daily basis
beginning on day 4 and cultures terminated on day 9, a
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time point associated with a robust cardiomyocyte gene
signature. This was done to evaluate cells at a similar time
point to that used in previous studies (Barrier et al., 2011;
Chandler et al., 2011).
EVALUATION OF MESC PROLIFERATION AND TRANSPORTER ACTIVITY
Cell number was estimated directly in culture plates by
washing 13 with PBS followed by fixing for 20 min in 4%
neutral buffered formalin. The cells were then washed 43
in PBS plus 0.1% Triton X100, 5 min each, and stained
with 1:1000 RedDot1 (Biotium Inc., Fremont, CA) in PBS
for 30 min. After staining, cells were washed 43 in PBS
plus 0.1% tween 20 for 5 min each and allowed to air dry
for a minimum of 48 hr before fluorescence determination
using the 700 nm channel of a LI-COR Odyssey near IR
plate scanner (Li-Cor Biosciences, Lincoln, NE).
K0143, a chemical inhibitor of ABCG2 (Allen et al.,
2002), and pheophrobide a (PhA), a specific fluorescent
substrate of ABCG2 and a compound used to measure
ABCG2 activity (Henrich et al., 2006), were initially eval-
uated for utility in our adherent culture system. K0143
was evaluated alongside its more commonly used conge-
ner, FTC. Verapamil and MK571, pharmacological inhibi-
tors of ABCB1 and ABCC1, respectively, were assessed as
well. mESC were treated on culture day 1 with transporter
inhibitors at a concentration range of 0 to 20 lM. 1 lM
PhA was added on culture day 3, approximately 20 hr
before plate scanning. The culture plate wells were then
washed 33 in PBS and scanned on a Spectramax M5 plate
scanner (Molecular Devices, Sunnyvale, CA) at excitation
and emission wavelengths of 395 and 670 nm, respec-
tively. After scanning, mESC were stained with RedDot1 to
normalize fluorescent signal to cell number. K0143 was
used at a concentration of 1 lM for all subsequent
experiments.
Modifications to the above protocols were used to eval-
uate ABCG2 activity in early culture where cell number
was limited and loss of cells after plate washing was
observed. Therefore, to achieve adequate signal, culture
plates to be evaluated on day 1 were initially seeded at a
density of 30,000 rather than 2500 cells per well using
250 ll media containing K0143 and PhA at a concentra-
tion of 1 lM each. The plates were then fixed in neutral
buffered formalin for 5 min before washing with PBS and
scanning. Day 4 culture plates used for comparison to
those scanned on culture day 1 were concurrently seeded
with 2500 cells per well in 250 ll media, treated with 1
lM K0143 and PhA on culture day 3, and similarly fixed
and scanned on culture day 4.
CAPILLARY-BASED IMMUNOASSAY
mESC were harvested on culture days 0, 2, 4, 6, and 9.
Collected cells were lysed in RIPA buffer (ProteinSimple,
San Jose, CA) containing inhibitors for both phosphatase
and protease (EMD Millipore) at 100 ng each. Lysates
were stored at 2208C. Protein concentration was deter-
mined using a Bradford Protein Assay kit according to
manufacturer’s directions (BioRad, Hercules, CA) with
absorbance measured on a CLARIOstar microplate reader
(BMG Labtech, Cary, NC) at 595 nm.
TABLE 1. Genes Used for Reverse Transcriptase-Polymerase Chain Reaction in mESC.
Gene name Gene symbol Marker type Taqman assay
Actin, beta Actb Housekeeping Mm00607939_s1
Nanog Nanog Pluripotency Mm02384862_g1
POU class 5 homeobox1 Pou5f1 Pluripotency Mm00658129_gH
Brachyury T Gastrulation/Mesendoderm Mm00436877_m1
Goosecoid Gsc Gastrulation/Mesendoderm Mm00650681_g1
Bone morphogenetic protein 4 Bmp4 Mesendoderm/Mesoderm Mm00432087_m1
GATA binding protein 4 Gata4 Mesendoderm/Endoderm Mm00484689_m1
Transthyretin Ttr Mesendoderm/Endoderm Mm00443267_m1
Neural cell adhesion molecule 1 Ncam1 Ectoderm Mm01149710_m1
Nestin Nes Ectoderm Mm00450205_m1
Desmin Des Mesoderm Mm00802455_m1
Myosin, heavy polypeptide 7 Myh7 Cardiomyocyte Mm01319006_g1
Myosin, light polypeptide 4 Myl4 Cardiomyocyte Mm00440378_m1
ATP-binding cassette,sub-familyG, mem2 Abcg2 Mm0049634_m1
ATP-binding cassette, sub-familyB, mem1 Abcb1 Mm00440736_m1
ATP-binding cassette, sub-familyC, mem1 Abcc1 Mm00456156_m1
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Protein expression analysis was conducted as directed
by the manufacturer on a Wes automated capillary-based
immunoassay platform (ProteinSimple, San Jose, CA) using
antibodies to ABCG2 (#GTX12131, GeneTex, Irvine, CA)
and GAPDH (#NB300-325, Novus Biologicals, Littleton,
CO). Chemiluminesce peak area was calculated by Gaus-
sian fit using Compass Software (version 3.1.7) and nor-
malized to GAPDH. One hundred nanograms of sample
was used per assay with antibody dilutions for ABCG2 and
GAPDH set at 1:300 and 1:200, respectively.
RNA PREPARATION AND CDNA SYNTHESIS
Total RNA was extracted using either TRIzol reagent
(ThermoFisher/Invitrogen) or RNAzol (Sigma-Aldrich)
according to vendor protocols by removing culture media
and adding lysis buffer directly to the wells of culture
plates. In general, four identically treated wells were
pooled per culture plate to ensure adequate RNA yield.
Recovered RNA was resuspended in RNase free water and
quantified using a ND-1000 NanoDrop spectrophotometer
(ThermoFisher). One microgram preparations were then
treated with RNase-free DNase (Promega) and cDNA syn-
thesized using a high capacity cDNA reverse transcription
kit (ThermoFisher/Applied Biosystems) according to
vendor-supplied protocols. cDNA was diluted to approxi-
mately 5 ng/ll assuming 100% reaction efficiency before
conducting Taqman assays.
TAQMAN REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE
CHAIN REACTION
Transcripts used for analysis are provided in Table 1.
Genes were selected based upon either common usage or
on unpublished data from our group which showed a
robust response across culture days. Amplifications were
conducted in 384 well plates using 12-ll reaction volumes
and amplification conditions provided by the vendor
(ThermoFisher/Applied Biosystems). All samples were run
on an ABI model 7900HT sequence detection system
according to the protocol supplied by the manufacturer.
Results were summarized using the 2-DDCt method (Livak
and Schmittgen, 2001).
STATISTICAL ANALYSIS
A biological replicate was considered the basic unit of
analysis and was defined as an individual culture plate
grown from a unique seeding of mESC. Replicate wells
within a culture plate were considered technical replicates
and averaged before statistical analysis. All data were
based on three independent biological replicates unless
otherwise indicated. Data were analyzed within JMP ver-
sion 7.0 (SAS, Cary, NC) by analysis of variance. Where
possible, experiment was included along with treatment as
model main effects. A Tukey-Kramer Honest Significant
Difference test was used for posthoc testing with a value
of p  0.05 used to determine significance.
Results
DIFFERENTIATION OF MESC GROWN IN TWO-DIMENSIONAL
ADHERENT CULTURE
Marker gene expression in untreated J1 cells is shown
across culture days in Figure 1A. Expression of Nanog and
Pou5f1, two standard markers of pluripotency (Nichols
et al., 1998; Mitsui et al., 2003), decreased over the culture
period, whereas, T (Brachyury) and Gsc, prospective
markers of vertebrate gastrulation (De Robertis et al.,
1994), peaked around culture day 4. There is a distinct
preference for formation of mesodermally-derived cardio-
myocytes when mESC are grown under maintenance con-
ditions in media containing serum, hence, genes associated
with cardiomyocyte differentiation such as Bmp4, Des,
Myl4, and Myh7 (Winnier et al., 1995; Hofner et al., 2007;
Christoforou et al., 2008; Kattman et al., 2011; Bag et al.,
FIGURE 1. Marker gene expression in untreated mESC. mESC grown in nondir-
ected 2D cultures are predisposed to differentiate into cardiomyocytes, hence,
increased expression of genes such as Bmp4, Des, Myl4, and Myh7 were
observed (A). Relative to other transcripts, expression of genes coding for
ABC efflux transporters remained relatively constant across the culture period
(B). Data are relative to culture day 0 and represent a single biological repli-
cate from pooled samples.
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2012) were found to increase in expression. Up-regulation
of TTr and Gata4 were observed as well.
Ttr a common marker of visceral endoderm and is
expressed in definitive endoderm (Goh et al., 2014), it is
also up-regulated in human cardiomyocytes (Synnergren
et al., 2008). Gata4, is expressed in definitive endoderm
(Rojas et al., 2010) but is also necessary for cardiomyocyte
fate determination (Holtzinger et al., 2010) and is found in
the murine heart (Arceci et al., 1993). Expression of the
neuroectoderm markers, Nes (Lendahl et al., 1990) and
Ncam1 (Bally-Cuif et al., 1993), did not change notably
suggesting that the formation of ectodermal cell types was
not favored under our culture conditions and is consistent
with the observation that cardiomyocyte formation was
the preferred lineage pathway. Transcripts for the three
ABC drug resistance transporters were readily detectable
and remained relatively uniform across the culture period
(Fig. 1B).
K0143 INHIBITED ABCG2 ACTIVITY IN MESC
Maximum inhibition of ABCG2 was achieved using approx-
imately 1 lM K0143 or FTC. Low PhA fluorescence was
observed following treatment with either verapamil or
MK571, thus confirming the specificity of PhA as a sub-
strate for ABCG2 in mESC (Fig. 2).
ABCG2 IS AN EFFECTIVE XENOBIOTIC EFFLUX TRANSPORTER IN MESC
An established role for ABCG2 is to serve as an efflux trans-
porter in a variety of tissues and cell types. This function
was evaluated in mESC by exposing J1 cells on culture day
1 to K0143 in combination with chemotherapeutics known
to be substrates of ABCG2. Effects on proliferation and dif-
ferentiation were then evaluated on culture day 4. Inhibi-
tion of ABCG2 increased the toxicity associated with
topotecan and mitoxantrone but, surprisingly, not doxorubi-
cin where it is possible that transporter redundancy may
have played a role (Fig. 3). Numerical fold change data and
FIGURE 2. Pharmacological inhibition of ABCG2 in mESC. Maximum inhibition of ABCG2 was observed at approximately 1 lM FTC or K0143 based on retention
of PhA, a specific fluorescent substrate of ABCG2. Minimal effects were observed for either verapamil (ABCB1 inhibition) or MK571 (ABCC1 inhibition). Treat-
ment with chemical inhibitors was initiated on culture day 1. PhA (1 lM) was added 20 hr before culture termination on day 4. Relative fluorescence was nor-
malized to cell number as determined by staining with RedDot1. Data are based upon a single experiment consisting of an average of culture plate well technical
replicates.
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statistical significance for individual genes are provided in
Supplementary Table S1, which is available online.
ABCG2 ACTIVITY INCREASES IN DIFFERENTIATING MESC
A significant increase in ABCG2 activity was observed when
transporter function on culture day 1 was contrasted to that
on culture day 4 (Fig. 4A). In this experiment, mESC were
co-treated with K0143 and PhA approximately 20 hr before
evaluation of PhA fluorescence. These results were further
supported using capillary-based immunoassay where a nota-
ble reduction in protein expression of ABCG2 was found on
culture day 2, although the level of ABCG2 protein expres-
sion on culture day 0 was found to be similar to that
observed on culture days 4 through 9 (Fig. 4B).
FIGURE 3. ABCG2 and xenobiotic transport in mESC. Cell number (A) and gene expression (B) were evaluated on culture day 4 following initiation of treatment on
culture day 1. Differential toxicity of topotecan and mitoxantrone, two chemotherapeutic agents, was observed following co-treatment with K0143. These data
indicate that ABCG2 provides protection from certain xenobiotics during early development. a, significance from control (p  0.05), b, significance from similarly
treated group not exposed to K0143 (p  0.05). Error bars, standard deviation.
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INHIBITION OF ABCG2 DOES NOT ALTER STEM CELL DIFFERENTIATION
Susanto et al. (2008) indicated that chemical or RNAi inhibi-
tion of ABCG2 in pluripotent mESC could alter the course of
stem cell differentiation. To evaluate whether ABCG2 serves
a fundamental role during early mESC differentiation, pluri-
potent mESC were seeded with and without K0143 on
culture day 0 and cells were evaluated for changes in prolif-
eration and differentiation on culture day 4. Cell number
and gene expression were unchanged (Fig. 5).
ABCG2 INHIBITION DOES NOT ALTER THE TOXICITY
OF TOXCAST PHASE I CHEMICALS
The effect of chemicals predicted by the ToxCast screening
program to regulate ABCG2 was evaluated with and with-
out co-treatment with K0143. As in our previous studies,
exposures were initiated on culture day 1 and treatment
effects evaluated on culture day 9 (Barrier et al., 2011;
Chandler et al., 2011). Based on cell number and marker
gene expression, co-treatment with K0143 did not alter
the toxicity induced by this group of xenobiotics (Fig. 6).
While greater expression of Ttr was observed at the high-
est concentration of propiconazole, the change was not
statistically significant. Numerical fold change data and
statistical significance for individual genes are provided in
Supplementary Table S2.
INHIBITION OF ABCG2 DOES NOT ALTER THE TOXICITY
OF OXIDATIVE STRESSORS
Chandler et al. (2011) proposed altered redox homeostasis
as a potential mode of action for ABCG2 and other path-
ways found to modify mESC differentiation. To evaluate
the role of ABCG2 during redox challenge, mESC were
treated with K0143 on culture day 3 along with known
oxidative stressors and evaluated approximately 20 hr
later. Negative effects on cell proliferation and gene
expression were readily observable with either tert-Butyl
hydroperoxide or paraquat; however, co-treatment with
K0143 had no influence on the cytotoxicity induced by
either treatment (Fig. 7). Numerical fold change data and
statistical significance for individual genes are provided in
Supplementary Table S3.
Discussion
The role of ABCG2 during mESC differentiation was eval-
uated with and without xenobiotic challenge. As a cellFIGURE 4. ABCG2 activity in mESC. ABCG2 activity increased during early
mESC differentiation based on retention of PhA. mESC were co-treated with
K0143 (1 lM) and PhA (1 lM) approximately 20 hr before evaluation of fluo-
rescence by plate scanning. Relative fluorescence was normalized to cell
number as determined by staining with RedDot1 (A). Reduced expression of
ABCG2 protein was observed on culture day 2 by capillary-based immunoas-
say. Note, similar results were obtained across two independent experiments
with measured variation principally related to differences in relative signal
between experiments (B). a, significance from control (p  0.05). Error bars
5 standard deviation.
FIGURE 5. Inhibition of ABCG2 and early mESC differentiation. Cell number
(A) and gene expression (B) were evaluated on culture day 4 following initia-
tion of treatment with K0143 on culture day 0. Inhibition of ABCG2 had no
effect on cell proliferation or marker gene expression. Error bars, standard
deviation.
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population average, the activity of ABCG2 was found to
increase during early mESC differentiation. Although the
established role of ABCG2 as a xenobiotic transporter
could be demonstrated using known chemotherapeutic
substrates, pharmacological inhibition of ABCG2 did not
alter mESC differentiation suggesting that, at least when
evaluated in an adherent culture system, ABCG2 is not
essential to the early stages of mESC differentiation. In
addition, inhibition of ABCG2 did not alter the toxicity of
various ToxCast chemicals indicating that the transporter
may not play a role in the mode of action of these chemi-
cals, a hypothesis previously suggested by our group
based on altered redox status. Along those lines, inhibition
of ABCG2 did not shift the toxicity of two oxidative stres-
sors raising a question about the role of ABCG2 in regulat-
ing redox status during early mESC differentiation.
The adherent culture system used in this study was
developed by our group as an alternative to assays which
rely on hanging drop culture and embryoid body forma-
tion (Barrier et al., 2011). In this system, mESC are grown
in two-dimensional (2D) adherent culture under mainte-
nance growth conditions containing FBS. Once feeder cells
and LIF are removed, there is a tendency for mESC to fol-
low a differentiation path toward cardiomyocyte formation
(Aouadi et al., 2006), although it should be stressed that
mESC do not proliferate in culture as a synchronized
FIGURE 6. ABCG2 inhibition and toxicity of EPA
ToxCast chemicals. Cell number (A) and gene
expression (B) in mESC exposed to propicona-
zole, flusilazole, pyridaben, rotenone, or imaza-
pyr with or without co-treatment with 1 lM
K0143. Cells were treated from culture day 1
through day 9. An interaction between chemi-
cal exposure and K0143 treatment was not
observed as would be expected based on the
hypothesis that certain xenobiotics influence
mESC differentiation by altering ABCG2 activity.
Imazapyr was included as a negative control.
Error bars. standard deviation.
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population of cells, hence, it is likely that cells at different
stages of differentiation and representing different cell lin-
eages were present in our cultures. Based on changes in
gene expression, this culture system provided a straight-
forward and dynamic system by which to evaluate mESC
differentiation.
While increased ABCG2 activity might be an important
characteristic of stem cell plasticity, or SP phenotype, in
several tissues (Summer et al., 2003; Martin et al., 2004;
Meeson et al., 2004; Cervello et al., 2010; Oka et al., 2010;
Fatima et al., 2012; Foster et al., 2013) it is not clear that
is the case in embryonic stem cells. Apati et al. (2008)
FIGURE 7. ABCG2 and oxidative stress in mESC. Cell number (A) and gene expression (B) were evaluated on culture day 4 following initiation of treatment on cul-
ture day 3. Co-treatment with 1 lM K0143 did not shift the toxicity of either tert-Butyl hydroperoxide or paraquat thus raising a question about the role of ABCG2
in maintaining redox homeostasis during early mESC differentiation. a, significance from control (p  0.05). Error bars, standard deviation.
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reported that both mRNA and protein levels of ABCG2
drop significantly in human embryonic stem cells (hESC)
following differentiation, however, conflicting data were
reported by Zeng et al. (2009). This was clarified by Pad-
manabhan et al. (2012), who found moderate levels of
ABCG2 transcript but no measurable protein in nondiffer-
entiated hESC cells. Erdei et al. (2013) further reported
that ABCG2 expression was not uniformly observed in plu-
ripotent hESC. The relationship between ABCG2 and
embryonic stem cell plasticity in mouse cells is also uncer-
tain. Sawicki et al. (2006) observed Abcg2 expression in
both the murine blastula as well as early stage embryos,
and Zeng et al. (2009) found ABCG2 protein in both undif-
ferentiated and differentiated mESC.
Vieyra et al. (2009), on the other hand, identified a dis-
tinct but somewhat heterogenous population of pluripo-
tent mESC that exhibited low Hoechst fluorescence along
with somewhat higher levels of Abcg2, Abcb1, and Abcc3
transcript, although the role of ABCG2 was not specifically
addressed. The question as to whether a subset of SP cells
can be found within the larger population of mESC was
not the focus of the current study; however, pluripotent
mESC were exposed to K0143, a specific inhibitor of
ABCG2, without negative effects on proliferation or early
differentiation. Thus, at least at the level of inhibition typi-
cally achieved by pharmacological compounds, reduced
activity of ABCG2 was not sufficient to disrupt normal dif-
ferentiation when pluripotent mESC were evaluated in an
adherent cell culture system. This supports the contention
that ABCG2 may not play a fundamental role in early dif-
ferentiation and is consistent with the observation that
ABCG2-null mice develop normally (Jonker et al., 2002).
An increase in ABCG2 transporter activity along with a
corresponding increase in ABCG2 protein expression was
also observed as mESC transitioned to a differentiated
state, although a relatively high level of ABCG2 protein on
culture day 0 was noted in our study as well. Whether a
decrease in ABCG2 activity after initial seeding of cells is a
true reflection of the biology of mESC or might somehow
be related to how these cells behave under in vitro condi-
tions is not clear. As cells of the inner cell mass, J1 embry-
onic stem cells represent cells of the hypoblast and
amniotic ectoderm as well as those of the embryonic epi-
blast. How these extraembryonic cells proliferate after ini-
tial plating is not certain but shifting cell populations
during the first few days of cell culture could contribute
to our results. Nevertheless, these data provide general
support to observations previously made in hESC which
suggest that ABCG2 activity increases during the early
stages of stem cell differentiation, at least within certain
cell lineages (Padmanabhan et al., 2012).
An important finding of this study was that ABCG2 is
not associated with the toxicity of ToxCast Phase I com-
pounds in mESC as previously theorized by our group
(Chandler et al., 2011). Twenty-two chemicals were
originally observed to be positive in both our in-house
stem cell assay as described by Barrier et al. (2011) as
well as the phase I ToxCast transcription activation assay
for ABCG2 which used primary human hepatocytes. This
group of chemicals drove the statistical significance dis-
cussed by Chandler et al. (2011). Only nine of these chem-
icals were found to alter stem cell differentiation, with the
remaining compounds causing cytotoxicity. Four of the
nine chemicals were then evaluated in the current study
with no interaction being observed between chemical inhi-
bition of ABCG2 and xenobiotic induced effects. While this
study was not broad in nature, we nevertheless believe it
unlikely that ABCG2 activity is related to the toxicity previ-
ously observed by our group.
A more credible explanation lies in the complex regula-
tion of ABCG2 (reviewed by Nakanishi and Ross, 2012).
The cis-regulatory elements within the ABCG2 promoter
include HRE (Krishnamurthy et al., 2004) and ARE (Singh
et al., 2010), potentially linking ABCG2 activity to the cellu-
lar response to hypoxia and oxidative stress. Furthermore,
regulation of ABCG2 by PXR has been demonstrated in
human cells (Lemmen et al., 2013) as has regulation by
AhR (Tan et al., 2010; To et al., 2011), although comparable
regulation of ABCG2 by AhR is less clear in mouse cells
(Tan et al., 2010). ABCG2 has also been shown to be regu-
lated by both PPARa (Eldasher et al., 2013) and PPARc
(Szatmari et al., 2006) which links ABCG2 activity to com-
pounds that act as peroxisome proliferators. Hence, it is
likely that regulation of ABCG2 is associated with xenobiotic
exposure in certain cells types. Several of these xenobiotics
would also be expected to show biological activity in mESC;
however, this relationship would not necessarily be one of
cause and effect. It is also worth noting that up-regulation
of Abcg2 transcript was not observed in these experiments.
Hence, regulation of Abcg2 in mESC may differ from that
observed in primary human hepatocytes, the cell type used
in the ToxCast ABCG2 transcription activation assay.
The idea that ABCG2 may play a role in regulating redox
status in mESC is well supported in the literature. Transcrip-
tional regulation of Abcg2 is influenced by HIF-1, and
ABCG2 has been shown to provide protection from hypoxic
condition in murine hematopoietic stem cells by transport-
ing excess porphyrins (Krishnamurthy et al., 2004). Indeed,
transport of porphyrins such as protoporphyrin IX, heme,
and hemin is an established function of ABCG2 (Jonker
et al., 2002; Robey et al., 2005; Zhou et al., 2005;
Desuzinges-Mandon et al., 2010), and mitochondrial damage
associated with elevated levels of protoporphyrin IX has
been observed in hepatocytes from Abcg2-null mice (Lin
et al., 2013). ABCG2 has also been shown to be regulated
by NRF2 (NFE2L2) in human cells (Adachi et al., 2007;
Singh et al., 2010) and in rodents (Wang et al., 2014).
Transport of glutathione may be yet a third mechanism
by which ABCG2 could influence redox status in mESC
(Brechbuhl et al., 2010; Higashikuni et al., 2012), although
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conflicting data have been reported (Gauthier et al., 2013).
Nevertheless, Zeng et al. (2012) found that reduced
ABCG2 activity was associated with lower levels of gluta-
thione and increased oxidative stress in the central nerv-
ous system of a transgenic murine model for Alzheimer’s
disease, and Krzyzanowski et al. (2014) reported that
overexpression of ABCG2 actually exacerbated the
response to oxidative stress in HepG2 cells potentially due
to increased efflux of glutathione. Hence, a link between
ABCG2 function and redox homeostasis might be expected
in mESC. It was, therefore, surprising that inhibition of
ABCG2 in mESC had no effect on the toxicity induced by
either tert-butyl hydroperoxide or paraquat and that tran-
scriptional regulation of Abcg2 was unaffected by oxidative
stress. These results require confirmation in other vitro
models. It is possible that the effects of ABCG2 in the cur-
rent study were not apparent as a cell population average
or that additional experimental times points were needed
to observe an effect. It is also possible that the treatments
used were in excess of the capacity for ABCG2 to modulate
redox status or that mESC grown in 2D culture may not
adequately reflect the in vivo environment of the early
embryo with regard to redox homeostasis.
In summary, the role of ABCG2 during the early stages
of mESC differentiation was examined both with and with-
out xenobiotic challenge using pharmacological inhibition
of ABCG2. Reduced ABCG2 activity did not alter normal
early mESC differentiation and did not shift the toxicity of
compounds predicted by ToxCast to regulate ABCG2. An
increase in transporter activity was observed during early
lineage differentiation. The supposition that a mechanistic
link exists between ABCG2 activity and xenobiotic toxicity
was not supported, although, a protective role for ABCG2
as a xenobiotic transporter was reaffirmed in mESC as it
has in other cells. Inhibition of ABCG2 did not shift the
toxicity of tert-Butyl hydroperoxide or paraquat thus rais-
ing a question about the role of ABCG2 in maintaining
redox homeostasis during early mESC differentiation. As
we continue to develop predictive models for developmen-
tal toxicants, modulation of ABCG2 activity may serve as
a useful endpoint. The current study, however, argues
against altered ABCG2 activity as a critical molecular ini-
tiating event associated with xenobiotic-induced dysmor-
phology during early development.
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Supplementary Table 1.  Average Fold Change on Culture Day 4 in mESC exposed to chemotherapeutics with and without K0143 co-
treatment1. 
Trt K0143 T  Gsc  Pou5f1  Nanog  Ttr  Bmp4  Gata4  Myh7  Abcg2  
Topotecan 15.8nM 0 µM 1.35±0.22 1.29±0.08 -0.37±1.82 -0.37±1.26 0.66±1.49 -0.39±1.24 -1.52±0.37 -0.49±1.33 -0.41±1.33 
Topotecan 50nM 0 µM 1.91±0.86 -1.12±0.12 0.26±1.53 -0.50±1.33 -1.39±2.17 1.11±0.09 -0.82±1.59 -0.58±1.46 0.43±1.59 
Topotecan 158nM 0 µM 0.37±1.29 -4.46±0.83* -2.76±2.00 -2.02±0.34* -2.43±0.57 1.37±0.18 -1.39±0.09 -0.37±1.33 -1.84±0.39* 
Mitoxantrone 0.5nM 0 µM 1.48±0.44 -2.17±0.13* -1.37±0.34 -1.48±0.11 -0.31±2.19 1.14±0.04 0.58±1.47 0.34±1.36 -0.46±1.36 
Mitoxantrone 1.6nM 0 µM -3.30±1.19* -14.02±2.66* -2.98±1.15 -4.46±1.65* -2.24±0.22 1.81±0.23* 1.78±0.52 1.94±0.23* -1.71±0.13 
Doxorubicin 4nM 0 µM -0.19±1.58 -2.57±0.29* -3.20±1.59 -1.93±0.05* -0.58±1.71 1.13±0.04 -0.24±1.71 -0.34±1.46 -1.58±0.35 
Doxorubicin 12.7nM 0 µM -12.96±3.38* -20.91±0.59* -6.40±3.19* -9.68±2.56* -1.48±2.56 1.96±0.23* 1.61±0.73 2.74±0.24* -1.94±0.28* 
           
Topotecan 15.8nM 1 µM 1.79±0.29 1.28±0.03 0.29±1.83 -1.31±0.11 -1.92±2.86 1.17±0.12 -0.49±1.41 -0.37±1.27 -1.30±0.23 
Topotecan 50nM 1 µM 1.53±0.42 -2.45±0.65* -0.61±1.57 -1.83±0.26 -2.78±2.69 1.60±0.20* 0.46±1.35 0.69±1.57 -1.36±0.25 
Topotecan 158nM 1 µM -17.23±5.05* -9.54±4.00* -3.59±0.53 -8.53±1.38* -0.86±2.31 1.95±0.72* 0.61±1.55 3.66±1.89* -0.75±1.59 
Mitoxantrone 0.5nM 1 µM -5.21±3.32* -13.87±3.56* -4.48±3.53 -4.92±2.05* -2.36±1.15 1.39±0.15* 1.33±0.15 1.99±0.43* -2.29±0.74 
Mitoxantrone 1.6nM 1 µM no RNA no RNA no RNA no RNA no RNA no RNA no RNA no RNA no RNA 
Doxorubicin 4nM 1 µM 0.40±1.50 -2.35±0.31* -1.87±1.21 -2.16±0.42* -1.57±0.36 0.42±1.28 0.21±1.75 0.34±1.17 -1.66±0.51 
Doxorubicin 12.7nM 1 µM -10.06±5.39* -16.42±4.27* -8.52±2.74* -10.26±1.89* -0.55±1.45 1.55±0.12* -0.51±1.41 2.93±0.61* -3.08±0.49* 
1Values = mean±SD 
* Significantly different than concurrent control (p≤0.05) 
 
 
Supplementary Table 2.  Average Fold Change on Culture Day 9 in xenobiotic-exposed mESC with and without K0143 co-
treatment1. 
Trt K0143 Bmp4 Nes Des Ttr Myl4 Myh7 Gata4 Abcg2 
Propiconazole 5 µM 0 µM -1.60±0.37 -0.29±1.30 -1.48±0.27 -1.65±0.12 -1.33±0.14 -3.29±0.71 -1.94±0.37 -0.54±1.44 
Flusilazole 5 µM 0 µM -1.68±0.21 1.47±0.22 -2.34±0.32* -1.33±2.54 -0.83±1.61 -10.50±1.00* -2.85±0.58 -1.28±0.15 
Pyridaben .015 µM 0 µM -2.74±1.28* -0.37±1.32 -11.18±7.53* -2.85±5.19 -2.06±0.67* -12.42±10.12* -4.48±3.69* -0.48±1.31 
Rotenone 0.005 µM 0 µM -1.38±0.23 -0.04±1.13 -1.76±0.27 2.71±0.60 -0.03±1.15 -1.03±0.93 1.46±0.16 0.00±1.33 
Imazapyr 5 µM 0 µM -1.21±0.04 -1.19±0.19 -1.33±0.22 -1.73±0.68 -1.13±0.07 -1.42±0.34 -1.54±0.33 -0.42±1.27 
Propiconazole 25 µM 0 µM -1.86±0.74 1.66±0.15 -2.70±0.93* -0.12±6.08 -1.88±0.60 -10.54±0.82* -1.81±0.55 0.33±1.30 
Flusilazole 25 µM 0 µM -1.80±0.68 1.74±0.28 -2.97±1.43* -22.69±33.6 -1.57±0.46 -13.15±3.74* -3.96±2.56* -0.32±1.41 
Pyridaben .075 µM 0 µM -2.26±0.76* -1.27±1.08 -19.55±7.08* -7.75±7.68 -3.07±0.40* -17.08±13.49* -3.27±2.61 -2.34±0.46* 
Rotenone 0.05 µM  0 µM -1.90±0.31* -0.05±1.11 -8.86±5.6* 4.53±3.13 -2.14±0.39* -2.51±1.51 1.85±0.54 -1.98±0.57* 
Imazapyr 25 µM 0 µM -1.11±0.02 -0.22±1.53 -1.10±0.05 -0.96±2.02 -1.10±0.03 -1.32±0.03 -0.41±1.48 1.15±0.12 
          
Propiconazole 5 µM 1 µM -1.32±0.07 1.27±0.17 -1.23±0.05 -1.49±0.44 -1.42±0.44 -3.04±1.39 -2.07±0.67 0.33±1.30 
Flusilazole 5 µM 1 µM -1.42±0.16 1.59±0.10 -2.06±0.06 0.14±1.57 -0.75±1.78 -8.79±3.59* -2.71±0.99 -1.25±0.18 
Pyridaben .015 µM 1 µM -2.37±1.05* 1.12±0.13 -10.47±5.93* -0.50±2.75 -2.17±0.60* -11.77±7.27* -2.01±0.22 -0.39±1.46 
Rotenone 0.005 µM 1 µM -0.95±0.81 0.05±1.36 -1.71±0.49 2.07±2.89 -0.36±1.35 -0.59±1.51 1.21±0.94 0.07±1.17 
Imazapyr 5 µM 1 µM -1.10±0.05 -0.43±1.33 -0.36±21.22 -0.84±1.61 -0.39±1.22 -0.58±1.47 -1.19±0.04 0.38±1.22 
Propiconazole 25 µM 1 µM -1.87±0.74 1.52±0.33 -2.73±0.53* 2.69±1.72 -2.14±0.84* -9.96±3.04* -2.23±1.11 -1.09±0.09 
Flusilazole 25 µM 1 µM -1.82±0.59 0.81±1.63 -3.51±1.43* -3.21±1.14 -1.62±0.56 -16.68±4.41* -5.58±3.16* -1.21±0.16 
Pyridaben .075 µM 1 µM -2.34±0.82* -1.10±0.05 -20.71±6.46* -2.94±5.88 -3.33±0.83* -18.94±13.00* -2.93±1.47 -2.22±0.11* 
Rotenone 0.05 µM  1 µM -1.75±0.56* 0.05±1.20 -7.77±4.49* 3.17±1.19 -2.15±0.31* -3.34±3.07* 1.40±1.22 -1.56±0.39 
Imazapyr 25 µM 1 µM -1.14±0.10 0.25±1.45 -1.25±0.18 -0.72±1.51 -0.48±1.29 -1.43±0.29 -1.39±0.23 -1.12±0.06 
1Values = Mean±SD 
*Significantly different than concurrent control (p≤0.05) 
 
Supplementary Table 3.  Average Fold Change on Culture Day 4 in mESC exposed to oxidative stress with and without chemical 
inhibition of ABCG21 
Trt K0143 T Gsc Pou5f1 Nanog Ttr Bmp4 Gata4 Myh7 Abcg2 
TBHP 100 µM 0 µM -1.27±0.17 -1.58±0.16 0.37±1.20 -1.12±0.13 -0.46±1.86 0.38±1.26 -0.41±1.43 0.52±1.47 -1.12±0.04 
TBHP 200 µM 0 µM -2.14±0.49 -2.95±0.76* -1.22±0.18 -1.60±0.13* -1.71±3.11 -1.13±0.10 -1.44±0.15 0.73±1.67 -1.37±0.12* 
TBHP 400 µM 0 µM -4.48±1.37* -7.40±4.84* -2.08±0.18* -3.68±0.82* -3.40±1.45 0.30±1.35 -1.12±0.07 1.64±0.24* -1.95±0.13* 
Paraquat 1 µM  0 µM -1.44±0.07 -1.82±0.11 1.32±0.14 0.35±1.28 0.41±1.70 -0.33±1.18 0.44±1.30 1.21±0.06 0.30±1.26 
Paraquat 10 µM 0 µM -2.07±0.21* -2.08±0.29* 1.20±0.11 -1.11±0.04 -0.28±2.57 -1.08±0.06 1.17±0.10 1.33±0.29 -1.16±0.02* 
Paraquat 100 µM 0 µM -8.89±4.28* -7.71±4.06* -1.51±0.18* -3.64±1.36* -4.75±1.83* -1.22±0.08* 0.31±1.24 2.36±0.28* -2.24±0.28* 
           
TBHP 100 µM 1 µM -1.47±0.13 -0.74±1.52 1.08±0.09 -0.45±1.26 -0.31±2.58 0.34±1.25 -0.49±1.63 1.37±0.33 -1.18±0.03 
TBHP 200 µM 1 µM -2.04±0.72 -2.50±0.37* -1.22±0.25 -1.50±0.48 -2.38±0.99* -0.40±1.33 -1.25±0.23 1.19±0.24 -1.34±0.15* 
TBHP 400 µM 1 µM -3.26±1.56* -3.10±1.88* -1.68±0.35* -2.70±0.42* -6.52±11.19 -0.36±1.24 -0.46±1.67 1.53±0.03* -1.72±0.14* 
Paraquat 1 µM  1 µM -1.66±0.17 -1.82±0.31 1.07±0.08 -1.08±0.03 -0.22±1.70 -0.33±1.24 1.20±0.21 1.23±0.17 -1.14±0.08 
Paraquat 10 µM 1 µM -2.48±0.52* -2.65±1.02* 0.39±1.22 -1.20±0.08 0.18±1.57 -0.45±1.26 0.35±1.32 -0.30±1.39 -1.25±0.16 
Paraquat 100 µM 1 µM -7.06±2.42* -4.71±1.62* -1.70±0.39* -3.48±1.05* -4.18±0.95* -1.50±0.08* 0.41±1.35 2.47±0.59* -2.47±0.53* 
1Values = mean±SD 
* Significantly different than concurrent control (p≤0.05) 
 
